Royalty Pharma plc Profit Margin

Royalty Pharma plc's profit margin stands at 32.14% as of June 2026. That compares with 44.26% in the prior-year period — down 27.4% year over year. That is above the Healthcare sector average of 13.89%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Royalty Pharma plc reported 32.14% in profit margin versus 44.26% a year earlier — a 27.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Royalty Pharma plc sits higher the Healthcare benchmark (13.89%) with a profit margin of 32.14%. That is roughly 131.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 32.14% for Royalty Pharma plc means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Royalty Pharma plc's profit margin evolved across reporting periods, while the comparison chart places RPRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.